{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-012530","form_type":"8-K","ticker":"ZBH","cik":"0001136869","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.490228+00:00","generated_at":"2026-06-06T05:21:18.499318+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zimmer Biomet Q4 2023 net sales $1.94B (+6.3%), adj EPS $2.20; guides FY24 adj EPS $8.00-$8.15","bullets":["Q4 net sales $1.94B (+6.3% reported, +6.1% CC); diluted EPS $2.01, adjusted $2.20.","Full-year 2023 net sales $7.39B (+6.5% reported, +7.5% CC); adjusted EPS $7.55.","FY 2024 guidance: constant currency revenue growth 5.0%-6.0%; adjusted diluted EPS $8.00-$8.15.","FDA closed out Warning Letter for Warsaw North Campus; global restructuring targeting ~$200M run-rate savings by 2025.","Completed $500M share buyback in Jan 2024; appointed Louis Shapiro to board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-012530","json":"https://secwatch.observer/filing/0000950170-24-012530.json","markdown":"https://secwatch.observer/filing/0000950170-24-012530.md","text":"https://secwatch.observer/filing/0000950170-24-012530.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024012530/0000950170-24-012530-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024012530/zbh-20240208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:21:18.499318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c8b4b195627d71c54d52bb610db1b67aa9c3c800","claim":"ZIMMER BIOMET HOLDINGS, INC. reported year ending December 31, 2024 results: revenue 2024 Reported Revenue Change 4.5% - 5.5%, EPS Adjusted Diluted EPS $8.00 - $8.15. Guidance reaffirmed.","evidence_excerpt":"The Company is providing the following full-year 2024 financial guidance: Projected Year Ending December 31, 2024 2024 Reported Revenue Change 4.5% - 5.5%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024012530/0000950170-24-012530-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ending December 31, 2024"},{"label":"Revenue","value":"2024 Reported Revenue Change 4.5% - 5.5%"},{"label":"EPS","value":"Adjusted Diluted EPS $8.00 - $8.15"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e807e7e8dc38ae0e048263835cabaf10a0fc1d5c","claim":"ZIMMER BIOMET HOLDINGS, INC. reported quarter and year ended December 31, 2023 results: revenue Fourth quarter net sales of $1.940 billion; Full-year net sales of $7.394 billion, net income Net earnings for the fourth quarter were $419.2 million; For the full year, net earnings were $1.024 billion, EPS Diluted earnings per share were $2.01 for the fourth quarter; Full-year diluted earnings per share were $4.88.","evidence_excerpt":"heather.zoumaslubeski@zimmerbiomet.com zach.weiner@zimmerbiomet.com Zimmer Biomet Announces Fourth Quarter and Full-Year 2023 Financial Results • Fourth quarter net sales of $1.940 billion increased 6.3% and 6.1% on a constant currency 1 basis • Fourth quarter diluted earnings per share were $2.01; adjusted 1 diluted earnings per share were $2.20 • Full-year net","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024012530/0000950170-24-012530-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and year ended December 31, 2023"},{"label":"Revenue","value":"Fourth quarter net sales of $1.940 billion; Full-year net sales of $7.394 billion"},{"label":"Net income","value":"Net earnings for the fourth quarter were $419.2 million; For the full year, net earnings were $1.024 billion"},{"label":"EPS","value":"Diluted earnings per share were $2.01 for the fourth quarter; Full-year diluted earnings per share were $4.88"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}